Quality of life and psychological state in patients with choroidal melanoma: Longitudinal study;Qualité de vie et état psychologique de patients atteints d'un mélanome de la choroïde: Étude longitudinale

Bulletin du Cancer

Volumn 98, Issue 2, 2011, Pages 97-107

  Suchocka Capuano, Agnieszka ^a,b   Brédart, Anne ^a,b   Dolbeault, Sylvie ^a,c,d   Lumbroso Le Rouic, Livia ^a   Lévy Gabriel, Christine ^a   Desjardins, Laurence ^a   Flahault, Cécile ^a,b   Bungener, Catherine ^b  

^a INSTITUT CURIE   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c INSERM   (France)

^d UNIVERSITÉ PARIS SACLAY   (France)

Author keywords

Cancer; Choroidal melanoma; Ophthalmology; Proton beam irradiation; Psychological state; Quality of life

Indexed keywords

IODINE;

ANXIETY; ARTICLE; CHOROID MELANOMA; CLINICAL EVALUATION; CONSERVATIVE TREATMENT; DEPRESSION; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; PHOTON THERAPY; PROSPECTIVE STUDY; PSYCHOLOGICAL ASPECT; QUALITY OF LIFE; SOCIAL STATUS;

EID: 79953250768     PISSN: 00074551     EISSN: 17696917     Source Type: Journal    
DOI: 10.1684/bdc.2011.1300     Document Type: Article

References (44)

1. Bunston T, Mackie A, Jones D, Mings D. Identifying the nonmedical concerns of patients with ocular melanoma. J Ophthalmic Nurs Technol 1994 ; 13 : 227-37.
2. Brandberg Y, Kock E, Oskar K, af Trampe E, Seregard S. Psychological reactions and quality of life in patients with posterior uveal melanoma treated with ruthenium plaque therapy or enucleation: a one year follow-up study. Eye 2000 ; 14 : 839-46. (Pubitemid 32040869)
3. Chabert S, Velikay-Parel M, Zehetmayer M. Influence of uveal melanoma therapy on patients' quality of life: a psychological study. Acta Ophthalmol Scand 2004 ; 82 : 25-31. (Pubitemid 38228658)
4. Reimer J, Voigtlaender-Fleiss A, Karow A, et al. The impact of diagnosis and plaque radiotherapy treatment of malignant choroidal melanoma on patients' quality of life. Psychooncology 2006 ; 15 : 1077-85. (Pubitemid 46040595)
5. Reimer J, Esser J, Fleiss A, et al. Quality of life in patients with malignant choroidal melanoma after radiotherapy. Graefes Arch Clin Exp Ophthalmol 2003 ; 241 : 371-7. (Pubitemid 36748572)
6. Melia M, Moy CS, Reynolds SM, et al. Quality of life after iodine 125 brachytherapy vs enucleation for choroidal melanoma: 5-year results from the Collaborative Ocular Melanoma Study: COMS QOLS Report No 3. Arch Ophthalmol 2006 ; 124 : 226-38. (Pubitemid 43247074)
7. Blanco-Rivera C, Capeans-Tome C, Otero-Cepeda XL. Quality of life in patients with choroidal melanoma. Arch Soc Esp Oftalmol 2008 ; 83 : 301-6.
8. Montazeri A, Vahdaninia M, Harirchi I, et al. Quality of life in patients with breast cancer before and after diagnosis: an eighteen months follow-up study. BMC Cancer 2008 ; 8 : 330.
9. Desjardins L. Le mélanome oculaire. [Electronic Version] Maladies des yeux. Le Syndicat national des ophtalmologistes de France, 2004, http:/www.snof.org/maladies/melanome-oculaire.html.
10. Goupillon-Senghor C, Giustranti C. Le mélanome de l'oeil. In : De la recherche de pointe aux traitements innovants à l'Institut Curie. Dossier de presse. 26 novembre 2009. Institut Curie, 2009.
11. Lyon/InVS/INCa/Francim/Inserm HCd. Projections de l'incidence et de la mortalité par cancer en France en septembre 2009.
12. Diener-West M, Hawkins B, Markowitz J, Schachat A. A review of mortality from choroidal melanoma. II. A meta-analysis of 5-year mortality rates following enucleation, 1966 through 1988. Arch Ophthalmol 1992 ; 110 : 245-50.
13. Diener-West M, Earle JD, Fine SL, et al. The COMS randomized trial of iodine 125 brachytherapy for choroidal melanoma, III: initial mortality findings. COMS Report No. 18. Arch Ophthalmol 2001 ; 119 : 969-82.
14. Isager P, Ehlers N, Overgaard J. Prognostic factors for survival after enucleation for choroidal and ciliary body melanomas. Acta Ophthalmol Scand 2004 ; 82 : 517-25. (Pubitemid 39386961)
15. Kodjikian L, Roy P, Rouberol F, et al. Survival after proton-beam irradiation of uveal melanomas. Am J Ophthalmol 2004 ; 137 : 1002-10. (Pubitemid 38759347)
16. Desjardins L, Lumbroso L, Levy-Gabriel C, et al. Prognostic factors for malignant uveal melanoma. Retrospective study on 2,241 patients and recent contribution of monosomy-3 research. J Fr Ophtalmol 2006 ; 29 : 741-9. (Pubitemid 44427485)
17. Hamrouni Z, Levy C, Lumbroso L, et al. Results of treating uveal melanoma with proton beam radiation: 10-year follow-up. J Fr Ophtalmol 2005 ; 28 : 833-9. (Pubitemid 41551459)
18. Desjardins L, Delage M, Lumbroso L, Levy C, Doz F. Cured after an intraocular tumor. Bull Cancer 2001 ; 88 : 1069-74. (Pubitemid 34020160)
19. Broman AT, Munoz B, Rodriguez J, et al. The impact of visual impairment and eye disease on vision-related quality of life in a Mexican-American population: proyecto VER. Invest Ophthalmol Vis Sci 2002 ; 43 : 3393-8. (Pubitemid 35334345)
20. Cruickshanks KJ, Fryback DG, Nondahl DM, et al. Treatment choice and quality of life in patients with choroidal melanoma. Arch Ophthalmol 1999 ; 117 : 461-7. (Pubitemid 29169640)
21. Melia BM, Moy CS, McCaffrey L. Quality of life in patients with choroidal melanoma: a pilot study. Ophthalmic Epidemiol 1999 ; 6 : 19-28. (Pubitemid 29312999)
22. Manschot WA, Lee WR, van Strik R. Uveal melanoma: updated considerations on current management modalities. Int Ophthalmol 1995 ; 19 : 203-9. (Pubitemid 26000312)
23. Brandberg Y, Damato B, Kivela T, Kock E, Seregard S. The EORTC ophthalmic oncology quality of life questionnaire module (EORTC QLQ-OPT30). Development and pre-testing (phase I-III). Eye 2004 ; 18 : 283-9. (Pubitemid 38455897)
24. Melia M, Moy CS, Reynolds SM, et al. Development and validation of disease-specific measures for choroidal melanoma: COMS-QOLS report No. 2. Arch Ophthalmol 2003 ; 121 : 1010-20. (Pubitemid 36841794)
25. Snaith RP, Zigmond AS. The Hospital Anxiety and Depression Scale with The Irritability-Depression Anxiety Scale and Leeds Situational Anxiety Scale. In : Manual. London : nferNelson, 1994.
26. Aaronson NK, Ahmedzai S, Bergman BB, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993 ; 85 : 365-76. (Pubitemid 23073154)
27. Guelfi JD. Les méthodes d́valuation clinique de l'anxiété. Suppl Act Med Inter Psychiatrie 1986 ; 3 : 65-70.
28. Razavi D, Delvaux N, Farvacques C, Robaye E. Validation de la version française du HADS dans une population de patients cancéreux hospitalisés. Rev Psychol App 1989 ; 39 :295-308.
29. Razavi D, Delvaux N, Farvacques C, Robaye E. Screening for adjustment disorders and major depressive disorders in cancer inpatients. Br J Psychiatry 1990 ; 156 : 79-83. (Pubitemid 20028157)
30. Snaith RP. Defining "depression". Am J Psychiatry 1987 ; 144 : 828-9.
31. Lepine JP, Godchau M, Brun P. Anxiety and depression in inpatients. Lancet 1985 ; 2 : 1425-6. (Pubitemid 16138576)
32. Lepine JP, Godchau M, Brun P, Lemperiere T. Evaluation of anxiety and depression among patients hospitalized on an internal medicine service. Ann Med Psychol (Paris) 1985 ; 143 : 175-89. (Pubitemid 15033841)
33. Spielberger CD. Manual for State-Trait Anxiety Inventory (Form Y) ("Self evaluation questionnaire"). CA: Consulting Psychologists Press Palo Alto, 1983.
34. Spielberger CD. State-Trait Anxiety Inventory: a comprehensive bibliography. CA: Consulting Psychologists Press Palo Alto, 1983.
35. Spielberger CD, Vagg PR. Psychometric properties of the STAI: a reply to Ramanaiah, Franzen, and Schill. J Pers Assess 1984 ; 48 : 95-7.
36. Bruchon-Schweitzer M, Paulhan I. Manuel pour l'inventaire d'Anxiété Trait-Etat (Forme Y). Université de Bordeaux II : Laboratoire de Psychologie de la Santé, 1990.
37. Borteyrou X, Bruchon-Schweitzer M, Spielberger CD. The French adaptation of the STAI-2, C. D. Spielberger's State-trait anger expression inventory. Encephale 2008 ; 34 : 249-55. (Pubitemid 351847621)
38. Demyttenaere K, Bruffaerts R, Posada-Villa J, et al. Prevalence, severity, and unmet need for treatment of mental disorders in the World Health Organization World Mental Health Surveys. JAMA 2004 ; 291 : 2581-90.
39. Üstün TB, Sartorius N. The background and rationale of theWHO Collaborative Study on "Psychological problems in general health care". In: Üstün TB, Sartorius N, (eds.), Mental Illness in General Health Care. An International Study. West Sussex : Wiley, 1995. p. 1-18.
40. Carlson LE, Angen M, Cullum J, et al. High levels of untreated distress and fatigue in cancer patients. Br J Cancer 2004 ; 90 : 2297-304.
41. Courtet PH, Collin G. Lombargies, douleurs chroniques et dépression. In: Orthopédique CdPLedM, (ed.), Santé mentale, appareil locomoteur et pathologies professionnelles. Sous direction de Fouquet, B. Lasfargues, G. Roquelaure, Y. Herisson, C. Paris : Masson, 2005.
42. Hopwood P, Howell A, Maguire P. Screening for psychiatric morbidity in patients with advanced breast cancer: validation of two self-report questionnaires. Br J Cancer 1991 ; 64 : 353-6.
43. American, Psychiatric, Association. Mini DSM-IV. Critères diagnostiques. Masson, 1996.
44. Simard S, Savard J. Fear of cancer recurrence inventory: development and initial validation of a multidimensional measure of fear of cancer recurrence. Support Care Cancer 2008 ; 17 : 241-51.